Frequency, indication and evolution of emergency cardiac surgery during TAVI

Original Title: Emergent cardiac surgery during transcatheter aortic valve implantation (TAVI): insight the Edwards SAPIENS Aortic Bioprosthesis Outcome (SOURCE) registry. Reference: Holger Eggerbrecht, et al. EuroIntervention 2014;10:975-81

SOURCE register data from patients receiving transcatheter aortic valve implantation with the Edwards Sapiens valve, were analyzed; out of 2307 patients, 27 (1.2%) required emergency cardiac surgery (ECS).

Valve stenosis was equally severe, but the aortic annulus diameter was larger in those that required ECS; this difference increased when using a

ECS causes were embolism/migration in 9 patients, aortic injury (dissection and perforation) in 7, aortic annulus rupture in 3, severe aortic regurgitation in 3, myocardial tamponade in 2, transapical bleeding in 1, heart block in 1 and suboptimal valve deployment in 1. 10 ECS patients died within 72 hours (VARC-2). At 30 days, mortality was 51.9% vs. 7.8% of those that did not require ECS (p<0.001). At 90 days, mortality was even higher, reaching 70% (19/27).

Conclusion

ECS rates in the context of TAVI is very low (1.2%), it should be performed with no delay and is associated with a 52% mortality rate at 30 days. Severe complications with acute evolution (annulus rupture or aortic injury) presented even higher mortality rates.

Commentary

This study, as well as others, has shown that although ECS during TAVI is not a frequent procedure, it unfortunately has high mortality rates within 90 days. This depends on the type of complications it may cause, and calls for a technological effort to develop more flexible and better adjusted valves to avoid these complications. 

Courtesy of Dr. Carlos Fava
Interventional Cardiologist
Favaloro Foundation – Buenos Aires

Carlos Fava

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

Therapeutic strategies in carotid free-floating thrombus: evidence and controversies

Carotid free-floating thrombus (cFFT) is a rare entity with a high embolic risk, associated with acute neurological events such as stroke or transient ischemic...